Neuroon Medical Technologies Corporation announces joint stock offering

All joint stock sold in the proposed supply will be sold by the company. In addition, the company plans to offer a 30-day option to purchase up to 15% of its shares in the offering. The proposed supply is subject to market and other conditions, and there can be no guarantee of when the supply will be completed or when or the exact size or terms of the supply.

The company’s proposed supply is refined for capital use and for general corporate purposes.

Craig-Halum Capital Group will be the sole management manager for the proposed supply.

The proposed supply is being processed in accordance with Form S-3 (File No. 333-256830) of the Securities and Exchange Commission (SEC). June 14, 2021. Pre-completion and related forecasts related to the proposed offering are recorded by the SEC and are available on the SEC website at www.sec.gov or Craig-Halum Capital Group LLC, 222 South Ninth Street, Suite 350; Minneapolis, MN 55402, Attn: Equity Capital Markets, call 612-334-6300 or email at prospectus@chlm.com.

This press release does not and will not be subject to the sale or request for the sale of any goods, nor shall the sale of these guarantees be made in any state or other state where such supply, request or sale is illegal. Prior to enrollment or qualification under such state or other authorized security laws. Any deductions, if at all, will only be made on the basis of the registration form, including “Postus”.

Neuroone Medical Technologies Corporation is a development company committed to providing minimally invasive and high-quality solutions for epilepsy, Parkinson’s disease, dystonia, major tremors, failed back surgeries and chronic pain. Other related neurological disorders that can improve patient outcomes and reduce operating costs. Visit https://www.n1mtc.com for more information.

Future Statements

This press release The provisions of Section 27a of the 1933 Amendment Act and Section 21E of the 1934 Amendment Law may include forward-looking statements. With the exception of historical facts, any information contained in this presentation may reflect the current outlook of the Company’s future and may be subject to other known and unknown hazards, uncertainties and other factors that may result in our actual results. Physically different activities, accomplishments, or achievements from the information presented or described in these future vision statements. In some cases, you can identify future expressions with the words “may”, “may”, “will”, “can”, “can”. “Purpose”, “Guess,” “Believe,” “Guess,” “Predict,” “Project,” “Potential,” “Target,” “Find,” “Think,” “Continue,” and “Continuous” or Terms negative, or another equivalent wording used to identify future statements. Future statements include statements related to the proposed supply and expected revenue. Although the company believes we have a reasonable basis for each future statement, we recommend that these statements be based on current facts and reasons and our expectations for the future, so we cannot be sure. Risk and uncertainty related to the market and other conditions, the satisfaction of normal closing conditions related to the planned public supply, the overall economic impact, and our real future outcomes may be different from what we expect materially due to factors beyond our control. In industry or political situations America Or, at the international level and in our file with the Security and Exchange Commission under the heading “Risk Factors”. These forthcoming statements are effective only from the date of this press release and the Company is under no obligation to review or update any new future statements for any reason, even if new information is available in the future.

SOURCE NeuroOne Medical Technologies Corporation